News | December 07, 2021
Study shows Glaxo-Vir drug works against Omicron mutations
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
The hospital is scheduled to open in 2024 with a bed capacity of 225
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
Subscribe To Our Newsletter & Stay Updated
